On January 6th, Insmed’s Chief Financial Officer, Sara Bonstein, sold 1,517 shares of company stock at an average price of $173.33 per share, generating proceeds of $262,941.61. Bonstein followed up with additional sales of 1,678 shares on January 7th for $293,767.46 and 1,447 shares on January 8th for $252,023.99. These transactions reduced her direct ownership from 85,148 to 83,631 shares, a 1.78% decline in her stake. Collectively, Bonstein’s sales, combined with transactions by the CEO, COO and other senior officers between January 6th and 8th, represent over $15 million in insider stock disposals. While such exits can reflect personal liquidity needs, they also carry the potential to dampen market sentiment, as concentrated selling by top executives may signal a view that current valuations are attractive for profit-taking.

In its latest strategic update, Insmed reaffirmed its full-year 2025 revenue guidance at approximately $606.4 million, exceeding the consensus estimate of $520.7 million by more than 16.5%. The company reported fourth-quarter BRINSUPRI revenues of $144.6 million and projects full-year 2025 sales of $172.7 million for its newly launched therapy. Meanwhile, its flagship product ARIKAYCE generated $433.8 million in 2025, surpassing prior guidance by 7.5%, and management now anticipates ARIKAYCE revenues of $450–470 million in 2026. These outperformance figures support Insmed’s multi-blockbuster narrative and underpin expectations for sustained cash flow growth, offsetting concerns over near-term R&D spend and potential trial-timing shifts in its Phase-3 and Phase-2b pipelines.